Back

Renal decline in patients with atrial fibrillation treated with rivaroxaban or warfarin: a population-based cohort study in the United Kingdom

27 August 2021 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Congress committee e-posters choice in pharmacology and pharmacotherapy Antiplatelet Drugs ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Doctor Yanina Lenz

Berlin (Germany)

17 More presentations in this session

Presentation thumbnail
Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients with atrial fibrillation on direct-acting oral anticoagulants
Mr A. Holt (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Usage and risk with phosphodiesterase type 5 inhibitors in male patients with chronic ischemic heart disease on oral organic nitrates
Mr A. Holt (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual kinetic mechanism of action
Mr Q. Ying (Ningbo, CN)
Abstract Slides
Presentation thumbnail
Antifibrotic and anti-inflammatory effects of the selective nonsteroidal MR antagonist finerenone in preclinical pulmonary fibrosis
Doctor M. Delbeck (Wuppertal, DE)
Abstract Slides
Presentation thumbnail
Aspirin vs. P2Y12 inhibitors with anticoagulation therapy for atrial fibrillation: insights from the AFIRE trial
Assistant Professor H. Fukaya (Sagamihara, JP)
Abstract Slides

Access the full session

Session thumbnail
Congress committee e-posters choice in pharmacology and pharmacotherapy

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention
thumbnail
Congress Presentation
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources